Orthocell (OCC) Q4 2024 TU earnings summary

Executive summary

• Achieved record quarterly revenue of $1.84 million in Q4 FY24, up 14.4% sequentially and 9.2% year-over-year.

• FY24 revenue reached $6.72 million, a 30.4% increase from FY23, driven by new product launches and distribution partnerships.

• Strong cash position with $20.60 million at quarter-end, supported by a $3.05 million R&D tax incentive refund.

• Continued expansion in global markets, with regulatory submissions and product launches in progress.

Financial highlights

• Quarterly revenue of $1.84 million in Q4 FY24, up from $1.61 million in Q3 FY24 and $1.68 million in Q4 FY23.

• FY24 revenue totaled $6.72 million, up from $5.15 million in FY23.

• Compound quarterly revenue growth rate of 9% over the last seven quarters.

• Net cash inflow from operating activities was $790k for the quarter.

• Cash receipts from customers were $976k for the quarter.

Outlook and guidance

• Well-funded for global expansion and US product registration for Remplir, expected in Q1 CY25.

• Top-line results from Remplir US market authorisation study expected in Q4 CY24, with US 510(k) submission on track.

• Exploring strategic partnerships for OrthoATI tendon cell therapy in the US to advance development without significant near-term investment.